At the end of the latest market close, Fennec Pharmaceuticals Inc. (FENC) was valued at $6.59. In that particular session, Stock kicked-off at the price of $6.60 while reaching the peak value of $7.63 and lowest value recorded on the day was $6.49. The stock current value is $7.63.Recently in News on August 22, 2022, Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor. ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~. You can read further details here
Fennec Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.63 on 09/20/22, with the lowest value was $4.11 for the same time period, recorded on 01/24/22.
Fennec Pharmaceuticals Inc. (FENC) full year performance was -10.24%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Fennec Pharmaceuticals Inc. shares are logging -24.29% during the 52-week period from high price, and 99.64% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $3.82 and $10.08.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 645017 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Fennec Pharmaceuticals Inc. (FENC) recorded performance in the market was 73.41%, having the revenues showcasing 36.62% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 202.27M, as it employees total of 10 workers.
The Analysts eye on Fennec Pharmaceuticals Inc. (FENC)
During the last month, 2 analysts gave the Fennec Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 6.27, with a change in the price was noted +1.95. In a similar fashion, Fennec Pharmaceuticals Inc. posted a movement of +34.33% for the period of last 100 days, recording 54,347 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for FENC is recording 0.59 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.47.
Technical rundown of Fennec Pharmaceuticals Inc. (FENC)
Raw Stochastic average of Fennec Pharmaceuticals Inc. in the period of last 50 days is set at 100.00%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 100.00%. In the last 20 days, the company’s Stochastic %K was 50.19% and its Stochastic %D was recorded 35.22%.
Considering, the past performance of Fennec Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 73.41%. Additionally, trading for the stock in the period of the last six months notably improved by 29.76%, alongside a downfall of -10.24% for the period of the last 12 months. The shares increased approximately by 14.56% in the 7-day charts and went down by 19.97% in the period of the last 30 days. Common stock shares were driven by 36.62% during last recorded quarter.